Bladder-sparing drug combo for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have muscle-invasive bladder cancer that has not spread to other parts of the body.
- Your tumor is mostly urothelial (the type of cell lining the bladder) and does not contain certain rare types.
- You are healthy enough for bladder removal surgery (cystectomy).
- You have a recent bladder tumor biopsy or sample that can be tested.
- You have not had previous treatments for advanced bladder cancer, and you haven't had radiation to the bladder.
- You do not have uncontrolled diabetes, active autoimmune disease, or certain eye or lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to see if they can control muscle-invasive bladder cancer without needing to remove the bladder. It may be an option for people who want to try to preserve their bladder and avoid surgery or radiation.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) to see if it can help people with muscle-invasive bladder cancer avoid bladder removal surgery. The goal is to preserve the bladder while still treating the cancer effectively.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) given before surgery to shrink or eliminate bladder or upper tract cancer. The goal is to see if this approach reduces the chance of cancer coming back and improves outcomes.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.